Merck inks MoU with Afrigen Biologics for development of mRNA vaccine technology platform

Aim of the collaboration is to develop mRNA platform technology, scale up and troubleshoot challenges in mRNA process optimization

Moderna announces positive Phase 3 efficacy data for next generation COVID-19 vaccine

Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older

Moderna & Merck announce 3-year data for mRNA-4157 in combination with Keytruda

The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer

Moderna receives U.S. FDA approval for RSV Vaccine mRESVIA

mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes

Takeda appoints Annapurna Das as the General Manager, India Operations

Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines

Moderna update on investigational RSV vaccine

U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024

Moderna posts Q1 2024 revenues at US$167 million

GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)

Apollo HealthCo to raise Rs. 2,475 crore from Advent International

Keimed is a leading wholesale pharma distribution with industry leading operating metrics

Syngene International reports Q4 FY24 consolidated PAT at Rs. 188.6 Cr

Syngene International has reported total income of Rs. 933 crores during the period ended March 31, 2024

Marksans Pharma updates on USFDA inspection at Verna, Goa manufacturing facility